U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939113) titled 'Real-World Effectiveness of Cabozantinib in Advanced Neuroendocrine Tumors: A Retrospective Multicenter Study Using the GTE-RENATEN National Database' on Nov. 10.
Brief Summary: Neuroendocrine tumors are rare tumors with prolonged survival. The management of patients at advanced stage is centered on both locoregional control and systemic therapy. Systemic approaches include somatostatin analogs (SSA) that improve symptom control and slow tumor progression, peptide receptor radionuclide therapy (PRRT), targeted agents (everolimus, sunitinib and cabozantinib) and chemotherapy. All these therapies have demonstrated clinical benefit acr...